| Issuer | % of Class | Filed |
|---|---|---|
|
Damora Therapeutics, Inc.
13G/A
Amendment 1
DMRA · 36322Q206
|
3.4% |
4/23/2026
Event 2/9/2026
|
|
Galecto, Inc.
13G
DMRA · 36322Q206
|
7.5% |
1/12/2026
Event 11/10/2025
|
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.